CONDENSED ABSTRACT (100 words max)
We compared the 3-year clinical outcomes of a novel thin strut cobalt chromium absorbable polymer sirolimus-eluting stent (APSES; MiStent) in a propensity matched analysis of 204 patients from the DESSOLVE I and II and the ISAR-TEST-4 studies. Target lesion failure (TLF) was lower at 12 months with APSES compared to EES (p=0.038) with no difference in stent thrombosis. At 3 years, TLF (p=0.02) and TLR (p=0.05) remained lower with APSES, with no additional stent thrombosis. TLF rates were similar between 1 and 3 years. These promising results may be MiStent design specific and need confirmation in a randomized clinical trial. (1) . Despite these benefits, durable polymer DES exhibit delayed vessel healing, hypersensitivity reactions and neoatheroma formation, resulting in delayed restenosis and repeat revascularization as well as late and very late stent thrombosis (2, 3) .
Bioabsorbable polymer coatings degrade over months to years and allow delivery of an antiproliferative drug until the polymer disappears leaving behind a bare metal stent. Limiting the duration of polymer exposure to the endothelial wall is intuitively attractive as this limits the inflammatory exposure to the duration necessary to deliver the anti-proliferative drug, thus offering potential for improved late safety and efficacy in comparison with durable polymer stents (4) .
The absorbable polymer sirolimus-eluting stent (APSES, MiStent; Micell Technologies, Durham, North Carolina) is a thin strut cobalt-chromium stent coated with crystalline sirolimus in a bioabsorbable polymer (see Figure 1 ). The combination of crystalline sirolimus within the bioabsorbable polymer enables the deposition of drug into the surrounding tissue and prolonged elution at a controlled rate, providing therapeutic tissue concentrations of sirolimus up to 9 months postimplantation, without an initial burst of drug release. The coating is cleared from the stent in 45 to 60 days -leaving behind a bare metal stent -and is absorbed into the tissue within 90 days. However comparative efficacy data against benchmark durable polymer DES remains scant.
The purpose of this analysis was to compare the 3-year clinical outcomes of the MiStent APSES with the durable polymer everolimus-eluting stent (EES; Xience , Abbot Vascular, Abbott Park, IL) using pooled data from 3 randomized trials and propensity score-matching to account for baseline differences in patient risk. (7) . Full details of the 3 trials have been published. DESSOLVE I was the First-in-Human experience with the APSES, enrolling 30 patients at 5 centers with symptomatic coronary artery disease with stable or unstable angina pectoris and lesions with >50% diameter stenosis, amenable to coverage with a < 23-mm long stent in vessel sizes of 2.5 to 3.5 mm in diameter (5) . Patients in consecutive groups of 10 underwent repeat angiography, intravascular ultrasound, and optical coherence tomography at 4, 6, or 8 months, and all patients had repeat angiography, intravascular ultrasound and optical coherence tomography at 18 months of followup. The primary endpoint was angiographic in-stent late lumen loss. DESSOLVE II included 184 patients at 26 centers, randomized in a 2:1 manner to APSES or the zotarolimus-eluting stent (ZES; Endeavor Sprint, Medtronic Vascular, Santa Rosa, CA). Patients were included if they had stable or unstable angina pectoris, a single, de novo, type A, B1 or B2 lesion of >50% diameter stenosis in a 2.5 to 3.5 mm diameter native coronary artery that could be covered with a ≤30 mm long stent (6) .
METHODS

Patient population and study design
Total occlusions, in-stent restenosis, highly calcified or thrombotic lesions and lesions located at major bifurcations or in highly tortuous vessels were excluded from the study. The primary efficacy hypothesis was superiority of in-stent late lumen loss (LLL) of APSES compared to ZES. The ISAR-TEST 4 trial was a randomized clinical trial with broad inclusion criteria, enrolling 2,603 patients at 2 clinics in Munich, Germany. Patients were randomized to either bioabsorbable polymer (N=1,299) or durable polymer DES (N=1,304); patients treated with durable polymer stents were randomly allocated to Xience EES (N=652) or SES (Cypher, Cordis, Miami Lakes, FL)(N=652) (7) . We included only the EES arm of ISAR-TEST-4 in this analysis. The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction (MI), or target lesion revascularization (TLR). A detailed comparison of inclusion and exclusion criteria for the DESSOLVE and ISAR-TEST-4 studies is reported in Supplementary Table 1 .
All patients were prescribed treatment with standard guideline-recommended dual antiplatelet therapy for 12 months.
Clinical Endpoints:
Clinical endpoint measures were collected prospectively within each trial using standard definitions, and endpoints in this analysis are a combination of each study's protocol-defined endpoints (detailed in Supplementary Table 2 ). The ISARESEARCH Center, Munich, Germany). Definitions of endpoints were similar across the three trials.
Angiographic Endpoints
In the DESSOLVE I trial, follow-up angiography was performed in consecutive groups of 10 patients at 4, 6, and 8 months, and in all patients at 18 months. In DESSOLVE II angiographic follow-up was performed at 9 months and in ISAR TEST- 
Statistical Analysis
The population for analysis and propensity score modeling was defined using the following rules: (1) only patients with single vessel intervention who received the study stent were included; (2) patients presenting with acute MI were excluded; and
(3) patients with total occlusions, thrombus, bifurcation lesions requiring side branch intervention, and ostial lesions were excluded.
Treatment groups were matched via propensity scores. A logistic regression was fit with treatment (APSES vs. EES) as the dependent variable against the following baseline covariates: age, sex, diabetes, smoking, hypertension, hypercholesterolemia, prior MI, prior PCI, prior bypass, and angina status (stable vs. non-stable), as well as whether or not the lesion required more than one stent and target vessel location (LAD, LCX, RCA), reference vessel diameter (RVD), lesion length, ACC/AHA classification, and moderate/severe calcification. The logistic regression model fit was assessed via Hosmer-Lemeshow. Patients were matched using the "greedy" algorithm with the maximum distance set at 0.1. A box plot of propensity scores before (but after applying exclusion criteria) and after matching was examined ( Supplementary Figure 1) .
All statistical analyses were performed using SAS statistical software and all statistical tests were conducted at the two-sided, 0.05 significance level. For categorical variables, the number and percentage within each category of the parameter are presented. For continuous variables, the mean, standard deviation, minimum and maximum values are presented. In the matched sample, data were compared between groups using methods appropriate for the matched (correlated) nature of the data. The primary outcome variable, TLF, is presented as Kaplan-Meier estimates and compared between groups via marginal hazard ratios (9) and 95% confidence intervals from the Cox proportional hazards regression using robust sandwich estimates of the variance. The assumption of proportionality was tested using the method of Lin, et al (10) .
As late angiographic follow-up was not planned/conducted in the DESSOLVE II study, sensitivity analyses were carried out to assess the robustness of the results to late angiographic follow-up for the primary outcome as follows: (1) 
RESULTS
A total of 805 patients (APSES=153; EES=652) were included in the overall analysis.
Propensity score matching was performed in 204 patients (APSES =102; EES=102).
Baseline Characteristics
Baseline patient characteristics between APSES and EES in the overall population are displayed in Table 1 . There were significant differences between the groups.
After matching, characteristics were well balanced between the groups ( Table 1) .
Mean age of the matched population was 66.5 years, 21% were diabetics, 24% had unstable angina. Overlap of the propensity scores was excellent as demonstrated by the box plots (Supplementary Figure 1 ). The propensity model fit was good as assessed by Hosmer-Lemeshow (P>0.05). The assumption of proportionality was not violated.
Baseline lesion characteristics between APSES and EES in the overall population are displayed in Table 2 . There were significant differences between the groups. After matching, characteristics were well balanced between the groups ( Table 2 ). The number of stents implanted and procedure success per patient was similar, but the maximum deployment pressure was higher in the EES group. The pre-procedure MLD was larger and the post-procedure MLD was smaller in the EES group (p<0.0001) resulting in a higher final in-stent and lesion diameter stenosis in the EES compared to the APSES group ( Table 2) .
Angiographic Outcomes
Results of angiographic follow-up are shown in Table 3 Table 3) .
Clinical Outcomes
In the matched population, APSES had significantly lower TLF (3% vs. 10%, p=0.038; Figure 2 ) and TLR (1% vs. 6%, p=0.05; (Figures 2-4) . 
DISCUSSION
In this propensity-matched analysis of pooled data from 3 clinical trials, the thin strut cobalt chromium MiStent APSES showed significantly lower rates of TLF at 1 year and at 3 years compared with the durable polymer Xience EES. These differences were driven by a significantly lower TLR rate at both time points.
Landmark analysis demonstrated that differences in TLF between APSES and EES occurred within the first year and was maintained at 3 years with minimal accrual beyond 1 year, and no difference in events between groups were observed from 1 to Based on our data, the achieved drug-release kinetic may confer benefit within the first year compared to the benchmark durable polymer EES; moreover, this benefit appears to be sustained between 1 and 3 years. The early benefit of the MiStent APSES may result from the unique combination of crystalline sirolimus within the bioabsorbable polymer, which enables the deposition of drug into the surrounding tissue with prolonged elution at a controlled rate. This unique design provides therapeutic tissue concentrations of sirolimus up to 9 months post-implantation, without an initial burst of drug release (12) . Unlike other bioabsorbable polymer DES, the MiStent polymer coating is cleared from the stent in 45 to 60 days and absorbed into the tissue within 90 days; long before complete drug elution. This unique prolonged drug elution resulting from the crystalline formulation of sirolimus (9 months) combined with a shorter polymeric absorption (3 months) may be associated with reduced inflammation (12) , and may well account for the observed lower rates of TLF and TLR at 1 year compared to the durable polymer EES platform observed in our study. Another important differentiating factor are the release kinetics of Mistent APSES, which lack the early drug release burst described with conventional DES (13) , and may mitigate an early dose related exaggerated vascular inflammatory effect.
A number of large-scale randomized clinical trials evaluating bioabsorbable polymer DES compared to the durable polymer EES have been recently reported and demonstrated generally comparable results in TLF at 9 to 12 months. The CENTURY II trial evaluated a thin strut cobalt-chromium stent releasing sirolimus from a poly-DL-lactic acid (PDLLA) and polycaprolactone co-polymer, which degrades over 3-4 months (14) . The 9-month TLF rate of the bioabsorbable polymer DES was similar (4.4% vs. 4.9%, p=0.66) compared to EES. The BIOSCIENCE randomized trial (15) evaluated a thin strut cobalt-chromium poly-L lactic acid polymer that degrades over 12-24 months. The 12 months TLF rates (6.7% vs. 4.1%) were non-inferior to the EES. Similar results were seen in the smaller BIOFLOW-II trial (16) . The EVOLVE II randomized trial evaluated a thin-strut platinum-chromium stent platform that delivers everolimus from a bioabsorbable poly(DL-lactide-coglycolide) (PLGA) polymer applied to the abluminal surface; this device has near synchronous drug release (90 days) and polymer absorption (120 days) (17) . At 12 months, TLF rates (6.7% vs. 6.2%, p=0.83) were non-inferior to the durable polymer Promus Element EES. The hypothesized benefit of bioabsorbable polymer DES is expected to become manifest first at late follow-up. In this respect, although the durable polymer EES demonstrates high efficacy at 9-12 months, accrual of events beyond 12 months has been described to occur at a rate of 2-3% per year in a large series of durable polymer DES (22). However, clear demonstration of long-term benefit with other bioabsorbable polymer DES remains to be shown. In the 3-year follow-up of the original ISAR TEST 4 trial, continued accrual of events occurred in both the durable and bioabsorbable polymer DES groups with no significant differences in clinical events discernable at 3 years with the biodegradable DES (23). Moreover, although long-term follow-up from the LEADERS trial as well as a pooled analysis including data from ISAR-TEST 3 and ISAR-TEST 4 showed improved late outcomes with bioabsorbable polymer DES the comparator stent in these analysis was the early generation Cypher SES (4, 24) . Indeed in a recent analysis of the final 5-year results from ISAR-TEST 4, we showed similar long-term results between bioabsorbable polymer DES and durable polymer EES (25) .
Whether our clinical findings reflect a design-specific advantage of the APSES is difficult to determine from our matched analysis and warrants confirmation in a randomized clinical trial. One cannot exclude that methodologic issues inherent to the design of our study may have played an important role. However, a matched propensity analysis allows us to assign a mechanistic basis to performance superiority. That one device is proven to have fewer target lesion and vessel failures, and with time less recoil acutely, less thrombosis in the subacute setting, less intimal hyperplasia and restenosis late not only removes ambiguity as to which device is better but explains why; in other words there is less lesion failure with the one because every design feature is superior on every aspect of vascular repair. This mechanistic superiority rather than simple clinical superiority emerges most when devices are constructed differently -the Mistent and Xience devices fall into this comparison as they are different in many respects. The MiCell APSES shows not simply superior acute performance that persists but rather continued incremental superiority in comparison to the EES Xience, offering the possibility that Mistent is superior for each of the fundamental elemental aspects of the vascular response to stenting -vasomotor response, thrombosis, cell migration and proliferation and tissue hyperplasia. Ultimately, our data suggests that the unique design properties of the MiStent APSES may offer early and sustained clinical benefit.
Limitations
The present study has some important limitations. First, a propensity matched analysis cannot completely correct for baseline confounding factors between the groups. Therefore, we cannot exclude the possibility that our results are due at least in part to residual unmeasured confounding. Second, the number of patients included is modest and this limits the ability of our study to detect differences between the groups especially in relation to rarely occurring clinical events. Third, interpretation of angiographic results is limited by the fact that quantitative coronary angiographic analysis was performed by different core labs for the DESSOLVE I and II studies in comparison with ISAR-TEST 4. However, the definitions of endpoints were similar, and the same software packages were used for analysis.
Conclusions
This propensity-matched analysis comparing the MiStent APSES to the durable polymer Xience EES showed significantly lower TLF rates at 1 year and at 3 years 
